We provide a rich training environment for the next generation of predoctoral students as well as postdoctoral and clinical fellows by leveraging community and industry support, institutional investment, infrastructure, and a critical mass of researchers and clinicians with extensive experience in muscle biology and muscular dystrophy.
Students interested in earning MS or Ph.D. degrees should submit online applications to the UCLA MS Program in Integrative Biology and Physiology or the UCLA Graduate Ph.D. Program in Bioscience. Indicate your interest in the “Muscle Cell Biology, Pathophysiology, and Therapeutics Training Program” in the personal statement of your application and alert Dr. Crosbie-Watson by email (add email address) once your application has been submitted. Faculty with muscle focused research programs are represented in many Home Areas within the Graduate Program in Bioscience. Students interested in discussing graduate school in muscle cell biology are invited to email Dr. Crosbie-Watson.
The UCLA Center for Duchenne Muscular Dystrophy at UCLA requests new applications for the Muscle Cell Biology, Pathophysiology, and Therapeutics Training Program. Predoctoral and Postdoctoral Positions available. The training program is open to any UCLA predoctoral (Ph.D. graduate students in 2nd year or beyond) or postdoctoral fellow who meets eligibility requirements and whose research interest focuses on muscle cell biology and disease. Application deadline is May 11, 2018 (midnight).
Additional muscle focused courses include:
The training faculty participate in an intensive course entitled PS156 (face-to-face) and PS121 (online) “Mechanisms and Therapies for Muscular Dystrophies.” The course is modeled upon extensive evidence-based pedagogy in STEM education and includes many innovations. Students are presented with a biological problem focused on an aspect of DMD, LGMD, and CMD. Students discover potential treatments and therapies to restore normal muscle function. This teaching format requires that students investigate basic molecular mechanisms of skeletal and cardiac muscle physiology.
Academic, industry, and patient advocacy groups are working together to fast-track FDA regulations for rare disease settings to permit greater translation of potential DMD treatments to the clinic. The surge of new treatments resulted from excellence in basic science and fruitful partnerships between academia and industry, together with efforts from advocacy groups, including the CDMD.